Insmed reported $2.08B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Cytokinetics USD 886.54M 69.51M Jun/2025
DBV Technologies USD 121.24M 92.09M Jun/2025
Dynavax Technologies USD 785.71M 30.26M Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Insmed USD 2.08B 678.89M Jun/2025
Novartis USD 25.94B 3.76B Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025